Company Insights

DXCM customer relationships

Explore interactive graphBrowse insights index
DXCM customer relationship map

DexCom (DXCM) — customer relationships, channel strategy, and partner risk

DexCom builds, manufactures and distributes continuous glucose monitoring (CGM) systems and monetizes primarily through recurring sales of disposable sensors, transmitters and related devices sold directly to patients and through channel partners; the business generates revenue globally (US-dominant) with a recurring, consumable revenue stream that supports strong gross margins and operating leverage. Investors should evaluate DexCom on two axes: the health of its direct-to-patient funnel (customer additions and retention) and the durability of strategic integrations with device partners and retail channels. For more in-depth relationship mapping and monitoring, visit https://nullexposure.com/.

Quick take: how customer sourcing translates to revenue and risk

DexCom’s commercial engine combines a direct sales force that targets clinicians and payors with distribution agreements that extend reach internationally and into retail. The company reports recurring sensor sales as the primary revenue driver and disclosed approximately 28% of revenue from outside the United States for the twelve months ended December 31, 2025, signaling meaningful international exposure alongside a US-dominant revenue base. Direct-to-patient purchasing behavior is central: DexCom’s products are purchased principally by individual patients and supported by insurance coverage in many cases, making end-user adoption and reimbursement dynamics core drivers of top-line growth.

Channel, product and geographic realities that matter

DexCom operates with a mix of selling motions — a direct sales organization in North America and select international markets, complemented by distributors in markets where direct coverage is not optimal. This contracting posture produces a dual set of advantages and risks: control over clinical education and payor relations in core markets, and faster scale via distributors and retail in markets where DexCom lacks direct presence. The company explicitly lists North America, Asia Pacific and EMEA among its commercial geographies, and added roughly 600k–700k net customers in 2025 excluding Stelo customers, underscoring both scale and continued customer acquisition capacity.

Public partner mentions: the relationships you should track

The public signals in the media and earnings transcripts highlight three distinct third-party relationships that reflect different commercial channels and integration strategies:

Amazon — retail placement for Stelo

An AthletechNews hands-on review (March 9, 2026) noted that Stelo by Dexcom was being sold on Amazon at a $99 price point, indicating DexCom’s use of mainstream retail channels for lower-priced or consumer-oriented product variants. This placement signals an expansion into retail distribution that can accelerate consumer adoption but will compress margins relative to direct clinical sales. Source: AthletechNews review, FY2026 (Mar 9, 2026).

Insulet Corporation (PODD) — sensor integration in Europe

Insulet’s Q4 2025 earnings call transcript referenced the launch of DexCom G7 integration in Germany, which Insulet identified as supporting solid performance across established European markets. This demonstrates that DexCom’s sensors are integrated into partner pump ecosystems, enhancing stickiness for end users who prefer combined pump/CGM solutions. Source: Insulet Q4 2025 earnings call transcript published on InsiderMonkey (FY2026).

Tandem Diabetes Care (TNDM) — broader pump platform integrations

Tandem’s Q4 2025 earnings call transcript disclosed that DexCom’s 15-day sensor integration is planned on both pumps and platforms globally, and that Tandem has product launches tied to DexCom integrations. This reflects a high degree of technical and commercial interdependence between DexCom and insulin pump manufacturers, which elevates the strategic importance of those relationships for recurring sensor attachment and long-term retention. Source: Tandem Q4 2025 earnings call transcript published on InsiderMonkey (FY2026).

What those relationships imply about DexCom’s operating model

  • Contracting posture: DexCom balances a direct, clinician-facing sales organization with distribution and retail agreements; this hybrid approach allows control in high-value markets while scaling quickly via third-party channels. The presence on Amazon for Stelo reflects a deliberate push into retail.
  • Concentration: Majority revenue is US-derived, but international sales are material — roughly 28% of revenue outside the US (twelve months ended Dec 31, 2025) — so geographic diversification reduces single-market dependence but introduces regulatory and reimbursement complexity.
  • Criticality: Integrations with insulin pump makers like Tandem and Insulet are strategically critical: these partnerships lock in users to DexCom sensors and create cross-selling and retention synergies. Loss or delay of partner integrations would have outsized commercial impact.
  • Maturity and stage: Relationships are active and commercial — earnings transcripts reference live launches and integrations; retail listings indicate that consumer-targeted SKUs are already in market. This suggests the model is in scale-out mode rather than pilot-only.

For more on how partner footprints translate to commercial exposure, see https://nullexposure.com/.

Key risks and what to watch

  • Channel margin pressure: Retail distribution (e.g., Amazon for Stelo) accelerates reach but pressures pricing and margins relative to clinician/insurance channels.
  • Partner integration dependency: Insulin pump integrations materially affect stickiness; any partner delays or interoperability issues would reduce future sensor demand. Monitor partner launch schedules and integration status.
  • International complexity: With nearly a third of revenue outside the US, currency volatility, local reimbursement changes, and distribution effectiveness are principal operational risks.
  • Customer concentration by type: Because products are purchased principally by individuals and supported by third-party payors, reimbursement policy shifts or payor denials can materially influence adoption and recurring revenue.

Operational indicators to track: country-level sales disclosure, net customer additions (including Stelo), partner integration milestones from pump manufacturers, and retail channel inventory/availability.

Bottom line for investors evaluating customer relationships

DexCom’s customer relationships span direct clinical channels, distributor networks and retail placements, while strategic integrations with pump manufacturers create a high-value ecosystem that feeds recurring disposable sensor demand. This combination produces robust recurring revenue but concentrates operational risk in partner integrations and international execution. For investors focused on customer-related exposure, prioritize monitoring partner rollout timelines (Tandem, Insulet), retail channel performance (Amazon listings for Stelo), and international revenue cadence.

If you want systematic coverage of customer relationships and channel risk across medtech peers, explore practical relationship intelligence at https://nullexposure.com/.

Conclude your diligence by tracking the three partner vectors described here: retail consumer rollout (Amazon), pump integrations (Tandem and Insulet), and international distributor performance — those are the most proximate levers for revenue trajectory and margin profile. For ongoing monitoring and alerts on these relationships, visit https://nullexposure.com/ for subscription options and deeper reports.